These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 5556771)

  • 1. [A drug for the treatment of essential hypertension].
    Meoni S; Costa S; Rossi R
    Minerva Med; 1971 Apr; 62(30):1581-7. PubMed ID: 5556771
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and efficacy of moxonidine in mild to moderate hypertension.
    Jain S; Malhotra P; Kumari S; Varma S
    J Assoc Physicians India; 2001 Aug; 49():829-30. PubMed ID: 11837474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension.
    Levine B
    Curr Med Res Opin; 2001; 17(1):8-17. PubMed ID: 11464450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Continuous automatic recording of blood pressure after administration of a new antihypertensive substance].
    Haan D
    Arzneimittelforschung; 1966 Sep; 16(9):1180-3. PubMed ID: 6014739
    [No Abstract]   [Full Text] [Related]  

  • 5. [Water-sodium depletion and clonidine in severe arterial hypertension].
    Sobel A; Safar M; Milliez P
    Maroc Med; 1972 Apr; 52(556):187-92. PubMed ID: 5042074
    [No Abstract]   [Full Text] [Related]  

  • 6. Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients.
    Robles NR; Martín-Agueda B; López-Muñoz F; Alamo C;
    Int J Clin Pract; 2005 Apr; 59(4):478-84. PubMed ID: 15853868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.
    Sharma AM; Wagner T; Marsalek P
    J Hum Hypertens; 2004 Sep; 18(9):669-75. PubMed ID: 15269705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative trial of timolol and flutonidin as antihypertensive agents.
    Salvadeo A; Segagni S; Villa G; Galli F; Piazza W; Bovio G
    Int J Clin Pharmacol Ther Toxicol; 1982 Feb; 20(2):78-84. PubMed ID: 7037661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hemodynamic studies on the long-term therapy with 2-(2,6-dichlorphenylamino)-2-imidazoline-hydrochloride].
    Lori M
    Dtsch Gesundheitsw; 1970 Jun; 25(23):1053-8. PubMed ID: 5524247
    [No Abstract]   [Full Text] [Related]  

  • 10. [Long-term treatment with a new antihypertensive drug: flutonidin].
    Nicrosini F; Pasotti C
    Minerva Med; 1983 May; 74(21):1297-300. PubMed ID: 6406947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of prolonged treatment with 2-(2,6-dichlorophenylamine)-2-imidazoline HCl on renal hemodynamics in arterial hypertension].
    Ludwig H
    Arzneimittelforschung; 1968 May; 18(5):600-4. PubMed ID: 5755891
    [No Abstract]   [Full Text] [Related]  

  • 12. Angiotensin receptor antagonists as a treatment for hypertension.
    MacFadyen RJ; Reid JL
    J Hypertens; 1994 Dec; 12(12):1333-8. PubMed ID: 7706690
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical and experimental study with the new blood pressure depressant 2-(2,6-dichlorphenylamino)-2-imidazole-hydrochloride].
    Grabner G; Michalek P; Pokorny D; Vormittag E
    Arzneimittelforschung; 1966 Sep; 16(9):1174-9. PubMed ID: 6014738
    [No Abstract]   [Full Text] [Related]  

  • 14. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
    Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
    J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hemodynamics changes during treatment of hypertensive patients with reserpine and Depressin].
    Lebedeva ZG; Ivanov IuM
    Klin Med (Mosk); 1968 Nov; 46(11):57-63. PubMed ID: 5746670
    [No Abstract]   [Full Text] [Related]  

  • 16. [A drug for therapy of essential hypertension].
    Meoni S; Costa S; Rossi R
    Minerva Med; 1971 Apr; 62(30):1581-7. PubMed ID: 5577288
    [No Abstract]   [Full Text] [Related]  

  • 17. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components.
    MacKay JH; Arcuri KE; Goldberg AI; Snapinn SM; Sweet CS
    Arch Intern Med; 1996 Feb; 156(3):278-85. PubMed ID: 8572837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of essential hypertension with the beta-receptor antagonist carteolol. A multicenter study].
    Rosprich G; Sölter H
    Arzneimittelforschung; 1983; 33(2a):334-9. PubMed ID: 6682326
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of treatment with eprosartan on pulse pressure: factors predicting response.
    de la Sierra A; Muñoz A; Arcos E; López JS; Relats J;
    Can J Cardiol; 2004 Oct; 20 Suppl C():17C-22C. PubMed ID: 16807619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension.
    Himmelmann A; Svensson A; Bergbrant A; Hansson L
    J Hum Hypertens; 1996 Nov; 10(11):729-34. PubMed ID: 9004102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.